Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism

[1]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. Germer,et al.  CIP2A Influences Survival in Colon Cancer and Is Critical for Maintaining Myc Expression , 2013, PloS one.

[3]  Shung-Haur Yang,et al.  BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy , 2012, Journal of surgical oncology.

[4]  C. Bokemeyer,et al.  Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. , 2012, European journal of cancer.

[5]  Kuen-Feng Chen,et al.  CIP2A is a target of bortezomib in human triple negative breast cancer cells , 2012, Breast Cancer Research.

[6]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[7]  A. Bardelli,et al.  Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas , 2012, Clinical Cancer Research.

[8]  M. Lundin,et al.  CIP2A overexpression is associated with c-Myc expression in colorectal cancer , 2012, Cancer biology & therapy.

[9]  Kuen-Feng Chen,et al.  CIP2A Is a Predictor of Poor Prognosis in Colon Cancer , 2012, Journal of Gastrointestinal Surgery.

[10]  P. Soares,et al.  The mTOR Signalling Pathway in Human Cancer , 2012, International journal of molecular sciences.

[11]  C. Haglund,et al.  Prognostic role of CIP2A expression in serous ovarian cancer , 2011, British Journal of Cancer.

[12]  Xinjun Dong,et al.  CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis , 2011, Annals of Surgical Oncology.

[13]  A. Cheng,et al.  CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells , 2010, Oncogene.

[14]  Guido Kroemer,et al.  Autophagy and the integrated stress response. , 2010, Molecular cell.

[15]  A. Ristimäki,et al.  CIP2A expression is increased in prostate cancer , 2010, Journal of experimental & clinical cancer research : CR.

[16]  E. Peng,et al.  Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways , 2010, Molecular carcinogenesis.

[17]  Jian Ding,et al.  Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways. , 2010, Journal of medical microbiology.

[18]  Z. Wang,et al.  ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy , 2010, Autophagy.

[19]  O. Kallioniemi,et al.  CIP2A Is Associated with Human Breast Cancer Aggressivity , 2009, Clinical Cancer Research.

[20]  B. Coiffier,et al.  Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Evan,et al.  MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. , 2009, Journal of the National Cancer Institute.

[22]  高張 大亮.  What's going on 進行結腸直腸がんに対してのオキサリプラチンを用いた一次治療におけるベバシズマブの上乗せ効果[Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J 'Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastati , 2009 .

[23]  J. Stebbing,et al.  Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear. , 2008, Future oncology.

[24]  C. Liu,et al.  CIP2A Is Overexpressed in Gastric Cancer and Its Depletion Leads to Impaired Clonogenicity, Senescence, or Differentiation of Tumor Cells , 2008, Clinical Cancer Research.

[25]  J. Westermarck,et al.  Mechanisms of MYC stabilization in human malignancies , 2008, Cell cycle.

[26]  R. Sears,et al.  CIP2A Inhibits PP2A in Human Malignancies , 2007, Cell.

[27]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[28]  D. A. Foster,et al.  mTOR-dependent Suppression of Protein Phosphatase 2A Is Critical for Phospholipase D Survival Signals in Human Breast Cancer Cells* , 2005, Journal of Biological Chemistry.

[29]  W. Hahn,et al.  Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. , 2005, Cancer research.

[30]  Jing-Yuan Fang,et al.  The MAPK signalling pathways and colorectal cancer. , 2005, The Lancet. Oncology.

[31]  S. Schreiber,et al.  Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Pieters,et al.  KIAA1524: A novel MLL translocation partner in acute myeloid leukemia. , 2011, Leukemia research.

[33]  Stephen L. Abrams,et al.  Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. , 2006, Advances in enzyme regulation.

[34]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.